Using human primary bronchial epithelial cells and smooth muscle cells (control: n = 6; asthma: n = 6, COPD: n = 6) the effect of EPs 7630 on the expression of virus docking proteins and rhinovirus infection was assessed. The scheme for treatment of primary epithelial cells is shown in Fig 1.  